相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Design, synthesis, and biological evaluation of phenyl thiazole-based AR-V7 degraders
Archana Bhumireddy et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2022)
Overview of the development of selective androgen receptor modulators (SARMs) as pharmacological treatment for osteoporosis (1998e2021)
Youquan Xie et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2022)
Targeted protein degradation: Emerging concepts and protein state-specific targeting principles
Andrew J. Tao et al.
CURRENT OPINION IN CHEMICAL BIOLOGY (2022)
Effects of MTX-23, a Novel PROTAC of Androgen Receptor Splice Variant-7 and Androgen Receptor, on CRPC Resistant to Second-Line Antiandrogen Therapy
Geun Taek Lee et al.
MOLECULAR CANCER THERAPEUTICS (2021)
Targeting transcriptional regulation of SARS-CoV-2 entry factors ACE2 and TMPRSS2
Yuanyuan Qiao et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2021)
An Overview of Next-Generation Androgen Receptor-Targeted Therapeutics in Development for the Treatment of Prostate Cancer
Michael L. Mohler et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2021)
Development of Novel Inhibitors Targeting the D-Box of the DNA Binding Domain of Androgen Receptor
Mariia Radaeva et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2021)
Discovery of A031 as effective proteolysis targeting chimera (PROTAC) androgen receptor (AR) degrader for the treatment of prostate cancer
Linrong Chen et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2021)
DCAF11 Supports Targeted Protein Degradation by Electrophilic Proteolysis-Targeting Chimeras
Xiaoyu Zhang et al.
JOURNAL OF THE AMERICAN CHEMICAL SOCIETY (2021)
Chemical Degradation of Androgen Receptor (AR) Using Bicalutamide Analog-Thalidomide PROTACs
Ga Yeong Kim et al.
MOLECULES (2021)
Targeted protein degraders crowd into the clinic
Asher Mullard
NATURE REVIEWS DRUG DISCOVERY (2021)
Resistance to second-generation androgen receptor antagonists in prostate cancer
Keith T. Schmidt et al.
NATURE REVIEWS UROLOGY (2021)
Designed, synthesized and biological evaluation of proteolysis targeting chimeras (PROTACs) as AR degraders for prostate cancer treatment
Jian-Jia Liang et al.
BIOORGANIC & MEDICINAL CHEMISTRY (2021)
Discovery of ARD-2585 as an Exceptionally Potent and Orally Active PROTAC Degrader of Androgen Receptor for the Treatment of Advanced Prostate Cancer
Weiguo Xiang et al.
JOURNAL OF MEDICINAL CHEMISTRY (2021)
Exploration and Biological Evaluation of Basic Heteromonocyclic Propanamide Derivatives as SARDs for the Treatment of Enzalutamide-Resistant Prostate Cancer
Yali He et al.
JOURNAL OF MEDICINAL CHEMISTRY (2021)
Strategies toward Discovery of Potent and Orally Bioavailable Proteolysis Targeting Chimera Degraders of Androgen Receptor for the Treatment of Prostate Cancer
Xin Han et al.
JOURNAL OF MEDICINAL CHEMISTRY (2021)
Development of an Androgen Receptor Inhibitor Targeting the N-Terminal Domain of Androgen Receptor for Treatment of Castration Resistant Prostate Cancer
Fuqiang Ban et al.
CANCERS (2021)
Structure-Activity Relationships for the Marine Natural Product Sintokamides: Androgen Receptor N-Terminus Antagonists of Interest for Treatment of Metastatic Castration-Resistant Prostate Cancer
Luping Yan et al.
JOURNAL OF NATURAL PRODUCTS (2021)
Selective androgen receptor modulators: the future of androgen therapy?
Andrew R. Christiansen et al.
TRANSLATIONAL ANDROLOGY AND UROLOGY (2020)
Androgen sensitivity gateway to COVID-19 disease severity
Carlos Gustavo Wambier et al.
DRUG DEVELOPMENT RESEARCH (2020)
Preclinical profile and phase I clinical trial of a novel androgen receptor antagonist GT0918 in castration-resistant prostate cancer
Tie Zhou et al.
EUROPEAN JOURNAL OF CANCER (2020)
Combination therapy with androgen receptor N-terminal domain antagonist EPI-7170 and enzalutamide yields synergistic activity in AR-V7-positive prostate cancer
Yukiyoshi Hirayama et al.
MOLECULAR ONCOLOGY (2020)
Pyrazol-1-yl-propanamides as SARD and Pan-Antagonists for the Treatment of Enzalutamide-Resistant Prostate Cancer
Yali He et al.
JOURNAL OF MEDICINAL CHEMISTRY (2020)
A highly potent PROTAC androgen receptor (AR) degrader ARD-61 effectively inhibits AR-positive breast cancer cell growth in vitro tumor growth in vivo
Lijie Zhao et al.
NEOPLASIA (2020)
Androgen Signaling Regulates SARS-CoV-2 Receptor Levels and Is Associated with Severe COVID-19 Symptoms in Men
Ryan M. Samuel et al.
CELL STEM CELL (2020)
Design and characterization of cereblon-mediated androgen receptor proteolysis-targeting chimeras
Akshay D. Takwale et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2020)
Bioactive Steroids from the Red Sea Soft Coral Sinularia polydactyla
Mohamed A. Tammam et al.
MARINE DRUGS (2020)
ODM-204, a Novel Dual Inhibitor of CYP17A1 and Androgen Receptor: Early Results from Phase I Dose Escalation in Men with Castration-resistant Prostate Cancer
Katriina J. Peltola et al.
EUROPEAN UROLOGY FOCUS (2020)
Discovery and development of ODM-204: A Novel nonsteroidal compound for the treatment of castration-resistant prostate cancer by blocking the androgen receptor and inhibiting CYP17A1
Riikka Oksala et al.
JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY (2019)
Design and synthesis of novel steroidal imidazoles as dual inhibitors of AR/CYP17 for the treatment of prostate cancer
Qiangqiang Hou et al.
STEROIDS (2019)
Tetrahydropyrazolo[1,5-a]pyridine-fused steroids and their in vitro biological evaluation in prostate cancer
Radek Jorda et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2019)
Orally Bioavailable Androgen Receptor Degrader, Potential Next-Generation Therapeutic for Enzalutamide-Resistant Prostate Cancer
Suriyan Ponnusamy et al.
CLINICAL CANCER RESEARCH (2019)
Synthesis of novel galeterone derivatives and evaluation of their in vitro activity against prostate cancer cell lines
Radek Jorda et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2019)
Galeterone and The Next Generation Galeterone Analogs, VNPP414 and VNPP433-3β Exert Potent Therapeutic Effects in Castration-/Drug-Resistant Prostate Cancer Preclinical Models In Vitro and In Vivo
Andrew K. Kwegyir-Afful et al.
CANCERS (2019)
Perspectives on the current and emerging chemical androgen receptor antagonists for the treatment of prostate cancer
Athanasios E. Dellis et al.
EXPERT OPINION ON PHARMACOTHERAPY (2019)
New Generation of Selective Androgen Receptor Degraders: Our Initial Design, Synthesis, and Biological Evaluation of New Compounds with Enzalutamide-Resistant Prostate Cancer Activity
Dong-Jin Hwang et al.
JOURNAL OF MEDICINAL CHEMISTRY (2019)
Discovery of ARD-69 as a Highly Potent Proteolysis Targeting Chimera (PROTAC) Degrader of Androgen Receptor (AR) for the Treatment of Prostate Cancer
Xin Han et al.
JOURNAL OF MEDICINAL CHEMISTRY (2019)
Molecules targeting the androgen receptor (AR) signaling axis beyond the AR-Ligand binding domain
N. G. R. Dayan Elshan et al.
MEDICINAL RESEARCH REVIEWS (2019)
A magic drug target: Androgen receptor
Dan Li et al.
MEDICINAL RESEARCH REVIEWS (2019)
Discovery of Highly Potent and Efficient PROTAC Degraders of Androgen Receptor (AR) by Employing Weak Binding Affinity VHL E3 Ligase Ligands
Xin Han et al.
JOURNAL OF MEDICINAL CHEMISTRY (2019)
Selective Androgen Receptor Modulators: Current Knowledge and Clinical Applications
Zachary J. Solomon et al.
SEXUAL MEDICINE REVIEWS (2019)
Development of Protein Degradation Inducers of Androgen Receptor by Conjugation of Androgen Receptor Ligands and Inhibitor of Apoptosis Protein Ligands
Norihito Shibata et al.
JOURNAL OF MEDICINAL CHEMISTRY (2018)
Androgen Receptor Targeted Treatments of Prostate Cancer: 35 Years of Progress with Antiandrogens
E. David Crawford et al.
JOURNAL OF UROLOGY (2018)
Development of selective androgen receptor modulators (SARMs)
Ramesh Narayanan et al.
MOLECULAR AND CELLULAR ENDOCRINOLOGY (2018)
Selectively targeting the dimerization interface of human androgen receptor with small-molecules to treat castration-resistant prostate cancer
Kush Dalal et al.
CANCER LETTERS (2018)
Synthesis and evaluation of novel thiazole-based derivatives as selective inhibitors of DNA-binding domain of the androgen receptor
Ruixue Xu et al.
CHEMICAL BIOLOGY & DRUG DESIGN (2018)
Androgen receptor degradation by the proteolysis-targeting chimera ARCC-4 outperforms enzalutamide in cellular models of prostate cancer drug resistance
Jemilat Salami et al.
COMMUNICATIONS BIOLOGY (2018)
Darolutamide (ODM-201) for the treatment of prostate cancer
Neal D. Shore
EXPERT OPINION ON PHARMACOTHERAPY (2017)
Novel Selective Agents for the Degradation of Androgen Receptor Variants to Treat Castration-Resistant Prostate Cancer
Suriyan Ponnusamy et al.
CANCER RESEARCH (2017)
Targeting Androgen Receptor Activation Function-1 with EPI to Overcome Resistance Mechanisms in Castration-Resistant Prostate Cancer
Yu Chi Yang et al.
CLINICAL CANCER RESEARCH (2016)
Sintokamide A Is a Novel Antagonist of Androgen Receptor That Uniquely Binds Activation Function-1 in Its Amino-terminal Domain
Carmen A. Banuelos et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2016)
Screening of synthetic and natural product databases: Identification of novel androgens and antiandrogens
Claudia Bobach et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2015)
Discovery and Development of Galeterone (TOK-001 or VN/124-1) for the Treatment of All Stages of Prostate Cancer
Vincent C. O. Njar et al.
JOURNAL OF MEDICINAL CHEMISTRY (2015)
Conversion of abiraterone to D4A drives anti-tumour activity in prostate cancer
Zhenfei Li et al.
NATURE (2015)
Androgen receptor: structure, role in prostate cancer and drug discovery
M. H. Eileen Tan et al.
ACTA PHARMACOLOGICA SINICA (2015)
Discovery of ODM-201, a new-generation androgen receptor inhibitor targeting resistance mechanisms to androgen signaling-directed prostate cancer therapies
Anu-Maarit Moilanen et al.
SCIENTIFIC REPORTS (2015)
Ligand-Independent and Tissue-Selective Androgen Receptor Inhibition by Pyrvinium
Minyoung Lim et al.
ACS CHEMICAL BIOLOGY (2014)
Identification of a Potent Antiandrogen that Targets the BF3 Site of the Androgen Receptor and Inhibits Enzalutamide-Resistant Prostate Cancer
Ravi S. N. Munuganti et al.
CHEMISTRY & BIOLOGY (2014)
Discovery of Small-Molecule Inhibitors Selectively Targeting the DNA-Binding Domain of the Human Androgen Receptor
Huifang Li et al.
JOURNAL OF MEDICINAL CHEMISTRY (2014)
Discovery of 1H-Indole-2-carboxamides as Novel Inhibitors of the Androgen Receptor Binding Function 3 (BF3)
Fuqiang Ban et al.
JOURNAL OF MEDICINAL CHEMISTRY (2014)
Characterization of Niphatenones that Inhibit Androgen Receptor N-Terminal Domain
Carmen A. Banuelos et al.
PLOS ONE (2014)
The Androgen-Regulated Protease TMPRSS2 Activates a Proteolytic Cascade Involving Components of the Tumor Microenvironment and Promotes Prostate Cancer Metastasis
Jared M. Lucas et al.
CANCER DISCOVERY (2014)
Glucocorticoid Receptor Confers Resistance to Antiandrogens by Bypassing Androgen Receptor Blockade
Vivek K. Arora et al.
CELL (2013)
Abiraterone Acetate in Combination with Prednisone for the Treatment of Patients with Metastatic Castration-Resistant Prostate Cancer: US Food and Drug Administration Drug Approval Summary
Paul G. Kluetz et al.
CLINICAL CANCER RESEARCH (2013)
Identification of Novel Androgen Receptor Antagonists Using Structure- and Ligand-Based Methods
Huifang Li et al.
JOURNAL OF CHEMICAL INFORMATION AND MODELING (2013)
An androgen receptor N-terminal domain antagonist for treating prostate cancer
Jae-Kyung Myung et al.
JOURNAL OF CLINICAL INVESTIGATION (2013)
Targeting the Binding Function 3 (BF3) Site of the Androgen Receptor Through Virtual Screening. 2. Development of 2-((2-phenoxyethyl) thio)-1H-benzimidazole Derivatives
Ravi Shashi Nayana Munuganti et al.
JOURNAL OF MEDICINAL CHEMISTRY (2013)
Systematic Structure Modifications of Multitarget Prostate Cancer Drug Candidate Galeterone To Produce Novel Androgen Receptor Down-Regulating Agents-as an Approach to Treatment of Advanced Prostate Cancer
Puranik Purushottamachar et al.
JOURNAL OF MEDICINAL CHEMISTRY (2013)
Characterization of a New Class of Androgen Receptor Antagonists with Potential Therapeutic Application in Advanced Prostate Cancer
Huifang Li et al.
MOLECULAR CANCER THERAPEUTICS (2013)
An F876L Mutation in Androgen Receptor Confers Genetic and Phenotypic Resistance to MDV3100 (Enzalutamide)
Manav Korpal et al.
CANCER DISCOVERY (2013)
A Clinically Relevant Androgen Receptor Mutation Confers Resistance to Second-Generation Antiandrogens Enzalutamide and ARN-509
James D. Joseph et al.
CANCER DISCOVERY (2013)
ARN-509: A Novel Antiandrogen for Prostate Cancer Treatment
Nicola J. Clegg et al.
CANCER RESEARCH (2012)
Interactions of Abiraterone, Eplerenone, and Prednisolone with Wild-type and Mutant Androgen Receptor: A Rationale for Increasing Abiraterone Exposure or Combining with MDV3100
Juliet Richards et al.
CANCER RESEARCH (2012)
Niphatenones, Glycerol Ethers from the Sponge Niphates digitalis Block Androgen Receptor Transcriptional Activity in Prostate Cancer Cells: Structure Elucidation, Synthesis, and Biological Activity
Labros G. Meimetis et al.
JOURNAL OF MEDICINAL CHEMISTRY (2012)
Steroid derivatives as pure antagonists of the androgen receptor
Sylvain Gauthier et al.
JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY (2012)
Design, synthesis and biological evaluation of nuclear receptor-degradation inducers
Yukihiro Itoh et al.
BIOORGANIC & MEDICINAL CHEMISTRY (2011)
Targeting the Binding Function 3 (BF3) Site of the Human Androgen Receptor through Virtual Screening
Nathan A. Lack et al.
JOURNAL OF MEDICINAL CHEMISTRY (2011)
New steroidal lactones as 5α-reductase inhibitors and antagonists for the androgen receptor
Mariana Garrido et al.
JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY (2011)
Regression of Castrate-Recurrent Prostate Cancer by a Small-Molecule Inhibitor of the Amino-Terminus Domain of the Androgen Receptor
Raymond J. Andersen et al.
CANCER CELL (2010)
Development of a Second-Generation Antiandrogen for Treatment of Advanced Prostate Cancer
Chris Tran et al.
SCIENCE (2009)
Targeted intracellular protein degradation induced by a small molecule: En route to chemical proteomics
Ashley R. Schneekloth et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2008)
Sintokamides A to E, Chlorinated Peptides from the Sponge Dysidea sp that Inhibit Transactivation of the N-Terminus of the Androgen Receptor in Prostate Cancer Cells
Marianne D. Sadar et al.
ORGANIC LETTERS (2008)
Crystal structure of the T877A human androgen receptor ligand-binding domain complexed to cyproterone acetate provides insight for ligand-induced conformational changes and structure-based drug design
Casey E. Bohl et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2007)
International Union of Pharmacology. LXV. The pharmacology and classification of the nuclear receptor superfamily: Glucocorticoid, mineralocorticoid, progesterone, and androgen receptors
Nick Z. Lu et al.
PHARMACOLOGICAL REVIEWS (2006)
Human androgen receptor gene ligand-binding-domain mutations leading to disrupted interaction between the N- and C-terminal domains
J Jääskeläinen et al.
JOURNAL OF MOLECULAR ENDOCRINOLOGY (2006)
Interplay between two hormone-independent activation domains in the androgen receptor
L Callewaert et al.
CANCER RESEARCH (2006)
Structural basis for antagonism and resistance of bicalutamide in prostate cancer
CE Bohl et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2005)
Chemistry and structural biology of androgen receptor
WQ Gao et al.
CHEMICAL REVIEWS (2005)
Design, synthesis, and biological characterization of metabolically stable selective androgen receptor modulators
CA Marhefka et al.
JOURNAL OF MEDICINAL CHEMISTRY (2004)
Evidence-based meta-analysis of pharmacotherapy for benign prostatic hypertrophy
O Ishizuka et al.
INTERNATIONAL JOURNAL OF UROLOGY (2002)
分享论文
